A coating composition for drug eluting medical devices, which is capable of forming a drug coating layer that is not susceptible to peeling during delivery to a target tissue is provided. This coating composition contains: a water-insoluble drug; at least one selected from the group consisting of hyaluronic acid, alkanoyl hyaluronic acids obtained by substituting at least part of hydrogen atoms in the hydroxyl groups of hyaluronic acid with an alkanoyl group, and salts of hyaluronic acid and the alkanoyl hyaluronic acids; and at least one selected from the group consisting of amino-acid esters and salts thereof. A drug coating layer, a medical device and a method of treatment are also provided.

An article is described including an article surface and a coating set comprising a tie coating or layer of SiO.sub.xC.sub.y or Si(NH).sub.xC.sub.y applied to the article surface, a barrier coating or layer of SiO.sub.x, and a pH protective layer of SiO.sub.xC.sub.y or Si(NH).sub.xC.sub.y. The respective coatings or layers can be applied by chemical vapor deposition of a polysiloxane or polysilazane precursor in the presence of oxygen. Examples of such an article are a prefilled thermoplastic syringe or thermoplastic pharmaceutical vial with a coated interior portion containing a pharmaceutical preparation or other fluid with a pH of 4 to 8, alternatively 5 to 9. The barrier coating or layer prevents oxygen from penetrating into the thermoplastic syringe or vial, and the tie coating or layer and pH protective coating or layer together protect the barrier layer from the contents of the syringe or vial.

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds containing boronate or boronic acid moieties that reduce degradation of the analyte indicator.

Injectable biopolymer compositions and associated systems and methods are disclosed herein. In some embodiments, a biopolymer composition for treating an aneurysm is provided. The biopolymer composition can include an injectable hydrogel including: a biopolymer; a chemical crosslinker forming covalent bonds with the biopolymer; and a stabilizer configured to inhibit ex vivo precipitation of the biopolymer. The injectable hydrogel can have an ex vivo storage modulus of at least 100 Pa at 37 C. over a linear viscoelastic region of the injectable hydrogel. The ex vivo storage modulus can be greater than an ex vivo loss modulus of the injectable hydrogel over the linear viscoelastic region of the injectable hydrogel.

A viscoelastic composition is disclosed which comprises (a) tris(hydroxymethyl)aminomethane or a salt thereof; (b) a phosphate buffer agent; and (c) a viscoelastic agent having an average molecular weight of about 100 to about 5,000,000.

Injectable biopolymer compositions and associated systems and methods are disclosed herein. In some embodiments, a biopolymer composition for treating an aneurysm is provided. The biopolymer composition can include an injectable hydrogel including: a biopolymer; a chemical crosslinker forming covalent bonds with the biopolymer; and a stabilizer configured to inhibit ex vivo precipitation of the biopolymer. The injectable hydrogel can have an ex vivo storage modulus of at least 100 Pa at 37 C. over a linear viscoelastic region of the injectable hydrogel. The ex vivo storage modulus can be greater than an ex vivo loss modulus of the injectable hydrogel over the linear viscoelastic region of the injectable hydrogel.

A device for supporting surgical procedures and method of its manufacture include preparing a glass melt in a silica crucible, injecting a gas bubble into the glass melt, shaping the glass melt containing the gas bubble into a phosphate glass structure having a tubular shape, cooling the phosphate glass structure, wherein the phosphate glass structure includes a network-forming component and a modifier, and truncating the phosphate glass structure into a desired length to form the device, wherein the device has a dissolution rate of at least 50 mg cm.sup.2 hr.sup.1.

An ophthalmic viscoelastic device includes at least one viscoelastic polymer, wherein the at least one viscoelastic polymer is cleavable into polymer chains of lower molecular weight, wherein the at least one viscoelastic polymer includes at least two polymer chains bonded to one another via at least one thermally and/or photochemically cleavable group, and wherein the at least one thermally and/or photochemically cleavable group is selected from compounds that can be coupled by a [2+2] cycloaddition and/or by click chemistry.